Recent News

• 12.17.2025 - FDA accepts Alnylam’s siRELIS TM enzymatic ligation manufacturing platform into its Emerging Technology Program, fast-tracking global regulatory engagement
• 12.17.2025 - $250M expansion of Norton, MA (USA) manufacturing facility announced; expansion will add enzymatic ligation manufacturing capability to meet growing demand for RNAi therapeutics
• 12.17.2025 - $250M expansion of Norton, MA (USA) manufacturing facility announced; expansion will add enzymatic ligation manufacturing capability to meet growing demand for RNAi therapeutics
• 12.17.2025 - FDA accepts Alnylam’s siRELIS TM enzymatic ligation manufacturing platform into its Emerging Technology Program, fast-tracking global regulatory engagement
• 11.03.2025 - Silence Disease Netherlands

Recent Filings

• 12.11.2025 - EX-99.1 EX-99.1
• 12.11.2025 - 8-K Current report
• 12.03.2025 - 8-K Current report
• 12.03.2025 - EX-99.1 EX-99.1
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 144 Report of proposed sale of securities
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors